Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results - 25/08/11
, Emmanuel Andrès, MD b, Jacques Zimmer, MD, PhD a, Esther Noel, MD b, Alina Zamfir, MD a, Argyro Koumarianou, MD a, Patrick Dufour, MD aAbstract |
Background |
Adults with chronic idiopathic thrombocytopenic purpura (ITP) in whom standard-dose corticosteroids and splenectomy have failed or who have contraindications to these therapies often require further treatment for life-threatening thrombocytopenia or bleeding. We studied whether danazol, an attenuated androgen, is useful in this setting.
Methods |
To assess both clinical outcome and tolerance issues, 57 patients who had refractory chronic ITP (n = 27) or who had contraindications to splenectomy or corticosteroids or who refused these therapeutic options (n = 30) were studied.
Results |
Thirty-eight patients experienced a partial or complete response to therapy (67%), among whom 27 (46%) remained in remission at a median (± SD) of 119 ± 45 months. Treatment tolerance was acceptable, although severe adverse events were reported in 9 patients (16%).
Conclusion |
Our findings suggest that danazol therapy may be beneficial in the management of refractory chronic ITP or when there are contraindications to splenectomy or corticosteroids (or both).
El texto completo de este artículo está disponible en PDF.Esquema
Vol 116 - N° 9
P. 590-594 - mai 2004 Regresar al número
Artículo precedente
- Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000
- Douglas S Lee, Muhammad M Mamdani, Peter C Austin, Yanyan Gong, Peter P Liu, Jean L Rouleau, Jack V Tu
- Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis
- Yannick Allanore, Didier Borderie, Hervé Lemaréchal, Ohvanesse Garabed Ekindjian, André Kahan
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?